AI Stock Analysis - Tempus AI (TEM)
Analysis generated October 13, 2025.
Tempus AI is a leading technology enterprise focused on leveraging artificial intelligence to provide innovative solutions across a range of industries. The company's core competencies include data analytics, machine learning, and AI-driven insights which are designed to optimize operations, enhance decision-making, and drive business growth. With a diverse portfolio of products and services, Tempus AI is positioned at the forefront of the AI market, catering to a broad clientele including healthcare, finance, and logistics sectors.
Stock Alerts - Tempus AI (TEM)
 |
Tempus AI | February 12 Price is down by -6.7% in the last 24h. |
|
Tempus AI | February 11 Price is down by -6.1% in the last 24h. |
|
Tempus AI | February 10 Business Outlook among employees is down by 4.8% over the last month. |
|
Tempus AI | February 10 Employee Rating is down by 3.3% over the last month. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Tempus AI
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 89 | Sign up | Sign up | Sign up |
| Sentiment | 97 | Sign up | Sign up | Sign up |
| Webpage traffic | 135,000 | Sign up | Sign up | Sign up |
| Employee Rating | 58 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| App Downloads | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Instagram Followers | 3,177 | Sign up | Sign up | Sign up |
| Reddit Mentions | 4 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 57 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 19,809 | Sign up | Sign up | Sign up |
| X Followers | 13,603 | Sign up | Sign up | Sign up |
| X Mentions | 50 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 3,140 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 40 | Sign up | Sign up | Sign up |
| Linkedin Employees | 2,957 | Sign up | Sign up | Sign up |
About Tempus AI
Tempus AI, Inc operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties.
| Price | $52.56 |
| Target Price | Sign up |
| Volume | 3,150,000 |
| Market Cap | $9.24B |
| Year Range | $50.78 - $103.25 |
| Dividend Yield | 0% |
| PE Ratio | 41.26 |
| Analyst Rating | 57% buy |
| Earnings Date | February 24 '26 |
| Industry | Health Care Services |
In the news
Median Technologies Signs Distribution Agreement With Tempus AI For Eyonis LCS Distribution To U.S. Imaging ProvidersFebruary 12 - Benzinga |
|
Tempus AI Has Been Awarded A $35.2M Veterans Affairs Contract For High-throughput Sample ProcessingFebruary 10 - Benzinga |
|
 |
Looking Into Tempus AI Inc's Recent Short InterestFebruary 8 - Benzinga |
Tempus AI: Staying Bullish On Leading Healthcare AI PlayJanuary 22 - SeekingAlpha |
|
 |
Tempus AI Highlights Strong Growth At The J.P. Morgan Healthcare ConferenceJanuary 21 - SeekingAlpha |
 |
Tempus AI, Inc. (TEM) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 12 - SeekingAlpha |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 334M | 128M | 206M | -80M | -37M | -0.110 |
| Q2 '25 | 315M | 120M | 195M | -43M | 9.1M | -0.220 |
| Q1 '25 | 256M | 101M | 155M | -68M | -74M | -0.400 |
| Q4 '24 | 201M | 79M | 122M | -13M | 12M | -0.180 |
| Q3 '24 | 181M | 75M | 106M | -76M | -51M | -0.250 |
Insider Transactions View All
| Epstein David R filed to sell 26,051 shares at $59.4. February 4 '26 |
| LEFKOFSKY ERIC P filed to sell 8,941,533 shares at $66.1. January 30 '26 |
| LEFKOFSKY ERIC P filed to sell 8,949,152 shares at $65.4. January 30 '26 |
| LEFKOFSKY ERIC P filed to sell 16,055,469 shares at $66.1. January 30 '26 |
| LEFKOFSKY ERIC P filed to sell 16,085,995 shares at $65.4. January 30 '26 |
Similar companies
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Nancy Pelosi |
Jan 26, 26 | Buy | $50K - $100K |
| Rob Bresnahan |
Jun 10, 25 | Buy | $1K - $15K |
| Nancy Pelosi |
Jan 20, 25 | Buy | $50K - $100K |
Read more about Tempus AI (TEM) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, app downloads, 4chan mentions, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Tempus AI
The Market Cap of Tempus AI is $9.24B.
As of today, Tempus AI's PE (Price to Earnings) ratio is 41.26.
Tempus AI will report its next earnings on February 24 '26.
Currently, the price of one share of Tempus AI stock is $52.56.
The TEM stock price chart above provides a comprehensive visual representation of Tempus AI's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Tempus AI shares. Our platform offers an up-to-date TEM stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Tempus AI (TEM) does not offer dividends to its shareholders. Investors interested in Tempus AI should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Tempus AI are Abbott Laboratories, HCA Healthcare, Cardinal Health, Henry Schein, and Idexx Laboratories.
